Audit: QRS - Rose Hip for Health & Longevity

Audit conducted on 21/08/2026 04:06 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	81
Failed	0
N/A	12
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: protocol cells to Therapeutic Protocol, time cells to Practical Considerations “Time to effect”, benefits/risks to the ER tier headings, gates to Key Interactions & Contraindications, markers to the ER monitoring table.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Hedges preserved, e.g. marker_9_target keeps “No rose-hip-specific target exists”; marker_4_why keeps “the speculative metabolic signal”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	“Pregnancy and lactation” remains under Contraindications, not Key Interactions; marker_1_why “may lower” matches ER “is proposed to lower”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid Rose Hip” list; Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor content appears in the gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, no NCT identifiers, no expert names (Winther is not carried over) and no brand names (Hyben Vital, Litozin, Rosenoids are all omitted).
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, funding-sceptical register, e.g. at_a_glance “Almost every positive trial was manufacturer-funded” mirrors the ER Conclusion.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Actionable protocol, time-to-effect and monitoring cells give the reader a path to act on while the evidence limits stay visible.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as findings and observed parameters, not as orders to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive verbs directed at a reader; the contraindication and interaction lists are stated as populations and drug classes.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Cadence and qualitative items are noun phrases (“Baseline panel before starting”, “Morning joint stiffness, recorded as minutes until it eases”), not recommendations.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are load-bearing (osteoarthritis, C-reactive protein, trans-tiliroside); at_a_glance uses plain equivalents such as “wear-related joint pain” and “deep abdominal fat”.
2.8	Information is presented in a concise and very compact manner	🟢	Benefit and risk items are reduced to the ER’s tier headings; explanations, magnitudes and mechanisms are stripped throughout.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Nine-marker monitoring panel with functional (not conventional-laboratory) targets addresses exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Gram-level split dosing with meals and a baseline-plus-follow-up laboratory panel assume a willing, effortful reader.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified general-population framing; targets such as “hs-CRP below 1.0 mg/L, ideally below 0.5 mg/L” are optimization-grade.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The manufacturer-funding caveat and the “weaker signals” framing give the risk-aware reader the discount factor the ER applies.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Uses “rescue analgesic”, “gastrointestinal upset and loose stools”, “transferrin saturation”; “loose stools” is the ER’s own clinical wording.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim at lines 440, 477, 519, 570, 589, 708, 539, 551, 593–595 and in the four tier <strong> labels of both the Benefits and Risks cards.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 fixed-name template spans are present, plus the repeatable marker_#_* (9 × 3) and qualitative_item_# (6) instances — 67 spans in total.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Head, CSS block, website="evidence_review", website="audit" and website="full_review" spans and the footer disclaimer are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section relied on by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Whole-fruit powder, the Danish approach”, action_2_label “Single versus split dosing” and action_3_label “Concentrated extract, the Japanese approach” reproduce the ER bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol labels are verbatim; the Time-to-effect labels derive from the ER’s own enumeration in the “Time to effect” bullet (joint pain, body-fat change, skin measures).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters occur in the file; the ER’s ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than transcribed: benefits and risks are reduced to tier headings, gate items to the key fact, monitoring “Why” cells to a single clause.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed anywhere in <body>.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: rose_hip_2026-0825-2358_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0821-0353.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: rose_hip_2026-0825-2358_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Rose Hip for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Rose Hip for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/21/2026, correctly derived from qrs_creation_date: 2026-0821-0353.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block (lines 415–428) contains only the template’s title and subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Line 433 compresses all three Conclusion paragraphs: constituents and action, strongest signal, weaker signals, safety limit, funding caveat.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion sentence, including “Safety is unusually benign” and “loose stools at higher intakes … the practical limit”.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “osteoarthritis” is rendered as “wear-related joint pain” and “visceral fat” as “deep abdominal fat”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, NCT identifier or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind; “modest” and “weaker” are used in place of magnitudes.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items come from the ER’s “Populations who should avoid Rose Hip” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-list entries are represented, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–546: five discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER rationale clauses were correctly stripped, e.g. “on the basis of absent safety data rather than demonstrated harm” and “where vitamin C loading and oxalate handling are both impaired”.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Thresholds retained: oxalate above 40 mg/day, ferritin 300/200 ng/mL, HFE C282Y homozygotes, filtration rate below 30 mL/min/1.73 m².
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in the contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	N/A	The section is not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map one-to-one onto the seven ER interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	No overlap with the five contraindication entries.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 554–560: seven discrete <li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Severity words, mechanisms and mitigations are all stripped; the em-dash clause “— blood thinners” after the vitamin K antagonist list was correctly removed.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs retained for cardiac glycosides, vitamin K antagonists, iron salts, NSAIDs and additive supplements.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in the interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	N/A	The section is not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Primary dose and form (5 g/day whole-fruit powder), dosing frequency and timing (split, with meals), and the alternative preparation (100 mg/day tiliroside extract).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Lines 444–472: all nine spans carry substantive, ER-traceable content.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Joint pain, body fat and skin measures — the three intervals the ER’s “Time to effect” bullet names.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the ER benefit tiers: joint pain (High), body fat (Medium), skin (Low).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; all three sets are populated.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Lines 483–511: “3 weeks”, “8–12 weeks” and “8 weeks” with ER-sourced sub-lines.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten items correspond to the ten ER benefit headings, tier for tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 521–532.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to the ER headings; the ER’s Magnitude figures (SMD 0.37, NNT six, 9.26 cm², 0.105 points) are all absent.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven items correspond to the seven ER risk headings, tier for tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 572–583.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The ER’s magnitude detail (11 events versus 2, dose-dependence, assay specifics) and the Expert Panel attribution are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Markers, targets and rationales all trace to the ER Monitoring Protocol & Defining Success table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows are present in the same order: hs-CRP, LDL cholesterol, systolic blood pressure, fasting glucose, HbA1c, waist circumference, ferritin with transferrin saturation, 24-hour urinary oxalate, serum digoxin.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 702 reproduces the ER’s baseline / four-week / three-month / six-to-twelve-month cadence plus the two-week digoxin and INR check.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER bullets are present in the same order, with trailing commentary clauses correctly trimmed.

Issues 21/08/2026 04:06

Pass rate 100.00%. No issues found.

Issues 21/08/2026 03:59

1. 4.2 / 4.3 — Protocol labels abbreviated: action_1_label (line 444) reads “Whole-fruit powder” and action_3_label (line 466) reads “Concentrated extract”, but the ER’s bold labels are “Whole-fruit powder, the Danish approach:” and “Concentrated extract, the Japanese approach:” (ER lines 342 and 344).
2. 4.5 — Exceeds one A4 page: The sheet’s estimated rendered height is roughly 1.9 A4 pages, driven by the nine-row Monitoring table (lines 599–699, ~130 mm), the gates block (lines 537–564, ~80 mm) and multi-line .sub, why and cadence fields carried over from the ER at near-full length.
3. 11.4 — Body-fat time cell holds generic caveat: time_2_sub (line 500) is “Nothing here works in days”, the ER’s closing general remark on ER line 399, and says nothing about the body-fat time course the “Body fat / 8–12 weeks” cell describes.

Fixes 21/08/2026 03:59

1. 4.2 / 4.3 — Protocol labels restored verbatim: action_1_label changed from “Whole-fruit powder” to “Whole-fruit powder, the Danish approach” and action_3_label from “Concentrated extract” to “Concentrated extract, the Japanese approach”, matching the ER’s bold labels.
2. 11.4 — Body-fat time cell made specific: time_2_sub changed from the generic “Nothing here works in days” to “Deep abdominal fat, in the 12-week extract trial”, describing the cell it sits under.
3. 4.5 — Prose condensed for the page budget: Shortened the nine Monitoring why cells, the marker_9 target, the cadence paragraph, the three protocol sub cells, the hemochromatosis contraindication and the “other interventions” interaction, and stripped trailing explanatory clauses from three qualitative items — all items retained, only wording tightened.